• Featured Product
  • KD/KO Validated

BRCA2 Polyklonaler Antikörper

BRCA2 Polyklonal Antikörper für ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, IHC, ELISA

Konjugation

Unkonjugiert

Kat-Nr. : 19791-1-AP

Synonyme

BRCA2, BRCC2, breast cancer 2, early onset, BROVCA2, FACD, FAD, FAD1, FANCB, FANCD, FANCD1



Geprüfte Anwendungen

Empfohlene Verdünnung

AnwendungVerdünnung
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Produktinformation

19791-1-AP bindet in WB, IHC, ELISA BRCA2 und zeigt Reaktivität mit human

Getestete Reaktivität human
In Publikationen genannte Reaktivitäthuman
Wirt / Isotyp Kaninchen / IgG
Klonalität Polyklonal
Typ Antikörper
Immunogen Peptid
Vollständiger Name breast cancer 2, early onset
Berechnetes Molekulargewicht 384 kDa
GenBank-ZugangsnummerNM_000059
Gene symbol BRCA2
Gene ID (NCBI) 675
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Antigen-Affinitätsreinigung
Lagerungspuffer PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
LagerungsbedingungenBei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

BRCA2, also named as FACD and FANCD1, is involved in double-strand break repair and/or homologous recombination. BRCA2 may participate in S phase checkpoint activation. Defects in BRCA2 are a cause of genetic susceptibility to breast cancer (BC) which also called susceptibility to familial breast-ovarian cancer type 2 (BROVCA2).

Protokolle

Produktspezifische Protokolle
WB protocol for BRCA2 antibody 19791-1-APProtokoll herunterladen
Standard-Protokolle
Klicken Sie hier, um unsere Standardprotokolle anzuzeigen

Publikationen

SpeciesApplicationTitle
humanWB

Nucleic Acids Res

LncRNA lnc-RI regulates homologous recombination repair of DNA double-strand breaks by stabilizing RAD51 mRNA as a competitive endogenous RNA.

Authors - Liping Shen
humanWB

Int J Biol Macromol

Antitumor efficacy of a recombinant EGFR-targeted fusion protein conjugate that induces telomere shortening and telomerase downregulation

Authors - Hong-Yu Tao
humanWB

Elife

LIN37-DREAM prevents DNA end resection and homologous recombination at DNA double-strand breaks in quiescent cells

Authors - Bo-Ruei Chen
humanWB

J Med Chem

Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA

Authors - Limei Ji
humanWB

Pharmacol Res

FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways.

Authors - Shi-Qi Wu
humanWB

Mol Cancer

The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy.

Authors - Yan Wang
  • KD Validated